Bladder Cancer

JAVELIN Bladder 100 Trial Impresses, Ensures Patients Have Access to Second-Line Immunotherapy at Disease Progression

July 07, 2020

Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.

Avelumab Plus Best Supportive Care Shows Efficacy in Urothelial Carcinoma

June 24, 2020

Petros Grivas, MD, PhD, discusses the JAVELIN Bladder 100 trial of maintenance avelumab plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.

Significant Benefit Not Seen With Frontline Pembrolizumab and Chemo for Advanced Urothelial Carcinoma

June 10, 2020

"While we are disappointed in these study results, Keytruda has been established as an important option in the treatment of metastatic bladder cancer, and we are committed to continuing our research to help more patients with this disease."

Infigratinib Active in Multiple Settings of Urothelial Cancer

June 03, 2020

"Our data suggests similar activity of infigratinib in patients receiving it in the first-line setting versus subsequent lines for advanced urothelial carcinoma."

DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer

May 31, 2020

"Irrespective of the PD-L1 status, there were no trends in favor of atezolizumab in both arms."

Frontline Avelumab Maintenance Prolongs Survival in Urothelial Carcinoma

May 28, 2020

"Avelumab first-line maintenance in patients whose disease has not progressed with platinum-based induction therapy is a new first-line standard of care for advanced urothelial carcinoma."

UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With Intermediate Risk

May 15, 2020

"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."

BCG-Unresponsive NMIBC Responds to Intravesical Adenoviral Gene Therapy

May 15, 2020

"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."

FDA Approves Mitomycin Gel For Low-Grade Upper Tract Urothelial Cancer

April 15, 2020

The FDA has granted approval to mitomycin gel as treatment of adult patients with low grade upper track urothelial cancer.